Welcome to EmpowHER and thank you for reaching out to our community for information on pulmonary fibrosis research.
For the benefit of all our readers, "pulmonary fibrosis occurs when lung tissue becomes damaged and scarred. This thickened, stiff tissue makes it more difficult for your lungs to work properly. As pulmonary fibrosis worsens, you become progressively more short of breath.
The scarring associated with pulmonary fibrosis can be caused by a multitude of factors. But in most cases, doctors can't pinpoint what's causing the problem. When a cause can't be found, the condition is termed idiopathic pulmonary fibrosis." Mayo Clinic
Are you asking specifically for research in new medications to treat this condition?
"Many people diagnosed with pulmonary fibrosis are initially treated with a corticosteroid (prednisone), sometimes in combination with other drugs that suppress the immune system — such as methotrexate or cyclosporine. Adding acetylcysteine, a derivative of a natural amino acid, to prednisone may slow the disease in some people. None of these combinations has proved very effective over the long run." Mayo Clinic
On October 15, 2014, the" FDA approved Ofev (nintedanib) and Esbriet (pirfenidone), two important new therapies for the treatment of patients with idiopathic pulmonary fibrosis (IPF) . Both drugs are “first-in-class” products that offer new hope for patients in the U.S. with IPF."
FDA Voice
Here is the link to the Pulmonary Fibrosis Foundation website for information regarding clinical trials. http://www.pulmonaryfibrosis.org/life-with-pf/clinical-trials
and research information for the medical community
http://www.pulmonaryfibrosis.org/medical-community
I hope this is the information you were looking for.
Comment Reply
Hello reckell2013,
Welcome to EmpowHER and thank you for reaching out to our community for information on pulmonary fibrosis research.
For the benefit of all our readers, "pulmonary fibrosis occurs when lung tissue becomes damaged and scarred. This thickened, stiff tissue makes it more difficult for your lungs to work properly. As pulmonary fibrosis worsens, you become progressively more short of breath.
The scarring associated with pulmonary fibrosis can be caused by a multitude of factors. But in most cases, doctors can't pinpoint what's causing the problem. When a cause can't be found, the condition is termed idiopathic pulmonary fibrosis." Mayo Clinic
Are you asking specifically for research in new medications to treat this condition?
"Many people diagnosed with pulmonary fibrosis are initially treated with a corticosteroid (prednisone), sometimes in combination with other drugs that suppress the immune system — such as methotrexate or cyclosporine. Adding acetylcysteine, a derivative of a natural amino acid, to prednisone may slow the disease in some people. None of these combinations has proved very effective over the long run." Mayo Clinic
On October 15, 2014, the" FDA approved Ofev (nintedanib) and Esbriet (pirfenidone), two important new therapies for the treatment of patients with idiopathic pulmonary fibrosis (IPF) . Both drugs are “first-in-class” products that offer new hope for patients in the U.S. with IPF."
FDA Voice
Here is the link to the Pulmonary Fibrosis Foundation website for information regarding clinical trials. http://www.pulmonaryfibrosis.org/life-with-pf/clinical-trials
and research information for the medical community
http://www.pulmonaryfibrosis.org/medical-community
I hope this is the information you were looking for.
Regards,
January 14, 2016 - 9:40amMaryann
This Comment
Reply